larotrectinib - For the treatment of unresectable locally advanced, or metastatic solid tumours with neurotrophic tyrosine receptor kinase (NTRK) gene fusion, according to clinical criteria
entrectinib - Treatment of patients with unresectable locally advanced, or metastatic solid extracranial tumours documented to have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, according to specific criteria